ODN1585 is used as a vaccine adjuvant; for research on acute myeloid leukemia (AML) and malaria; induces regression of established melanoma in mice; provides complete protection against malaria in mice; enhances CD8+ T cell function, including IFN-γ production; and acts as a potent stimulator of natural killer (NK) cells and inducer of IFN and TNF-α production.